NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Lung cancer remains the leading cause of cancer-related death, and it is usually diagnosed in advanced stages (stage III or IV). Recently, the availability of targeted strategies and of immunotherapy with checkpoint inhibitors (ICI) has favorably changed patient prognosis. Treatment outcome is close...

Full description

Bibliographic Details
Main Authors: Virginia Liberini, Annapaola Mariniello, Luisella Righi, Martina Capozza, Marco Donatello Delcuratolo, Enzo Terreno, Mohsen Farsad, Marco Volante, Silvia Novello, Désirée Deandreis
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
immune checkpoint inhibitors
non-small cell lung carcinoma
PD-1
PD-L1
immune PET
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/13/18/4543

Internet

https://www.mdpi.com/2072-6694/13/18/4543

Similar Items